# Tianjin Kedao Boji Biotechnology Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/tianjin-kedao-boji-biotechnology-co

- Industry: Healthcare
- Headquarters: Tianjin, China
- Latest round: Angel (Jul 23, 2025)
- Investors on record: 1

## About

Founded in 2024 and based in Tianjin, China, Tianjin Kedao Boji Biotechnology Co., Ltd. engages in research and development in the field of cell therapy. The company is backed by a team of experienced researchers with expertise in cell culture, gene editing, and immune therapy. In July 2025, the company received an angel funding. 

The company focuses on the R&D and commercialization of cell therapy technologies, including cell culture and expansion systems, gene editing platforms, immune cell therapy products and translational solutions for clinical application. The company generates revenue through research contracts, licensing of cell therapy technologies and customized development services. The company plans to utilize the funds raised to expand R&D investment, optimize manufacturing processes and accelerate clinical trial progress for its cell therapy pipeline, with the goal of bringing innovative treatments to market.

## Funding rounds

- Angel, Jul 23, 2025 — Tianjin Venture Capital

## Investors

- Tianjin Venture Capital (https://capitalatlas.ai/funds/tianjin-venture-capital) — Angel